Arina V. Orikhan-Zinkina
Saint Petersburg, SPE 198515, Russian Federation
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications
The Efficacy and Safety of Divozilimab in Patient with Systemic Sclerosis: 48-Week Results of the Randomized Double-Blind Placebo-Controlled Phase III Clinical Study LIBERIUS.
Journal: Doklady. Biochemistry and biophysics
Published: February 20, 2026
Corrigendum to "Improved clinical outcomes with low-dose anti-CTLA-4 (Nurulimab) plus anti-PD-1 (Prolgolimab) vs. anti-PD-1 monotherapy in advanced cutaneous melanoma: Results from the phase III OCTAVA trial" [Eur J Cancer. 227 (2025) 115674].
Journal: European journal of cancer (Oxford, England : 1990)
Published: August 31, 2025
Results of 4 years of therapy with divozilimab in patients with relapsing multiple sclerosis
Journal: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
Published: August 08, 2025
Improved clinical outcomes with low-dose anti-CTLA-4 (Nurulimab) plus anti-PD-1 (Prolgolimab) vs. anti-PD-1 monotherapy in advanced cutaneous melanoma: Results from the phase III OCTAVA trial.
Journal: European journal of cancer (Oxford, England : 1990)
Published: June 15, 2025
The Efficacy and Safety of BCD-180, an Anti-TRBV9+ T cell Monoclonal Antibody, in Patients with Active Radiographic Axial Spondyloarthritis: 36-week Results from the Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Study ELEFTA.
Journal: Doklady. Biochemistry and biophysics
Published: February 03, 2025
Natural history of spinal muscular atrophy type I
Journal: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
Published: December 18, 2024
Prolgolimab with chemotherapy as first-line treatment for advanced non-squamous non-small-cell lung cancer.
Journal: European journal of cancer (Oxford, England : 1990)
Published: August 23, 2024
Long-term efficacy and safety of divozilimab during 2-year treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-4/MIRANTIBUS
Journal: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
Published: April 27, 2024
Efficacy and Safety of Levilimab in Combination with Methotrexate in Patients with Active Rheumatoid Arthritis: 56-Week Results of Phase III Randomized Double-Blind Placebo-Controlled Trial SOLAR.
Journal: Doklady. Biochemistry and biophysics
Published: April 25, 2024
A phase III study to access the safety and efficacy of prolgolimab 250 mg fixed dose administered every 3 weeks versus prolgolimab 1 mg/kg every 2 weeks in patients with metastatic melanoma (FLAT).
Journal: Frontiers in oncology
Published: February 13, 2024
Efficacy and safety of antiCD20 monoclonal antibody divozilimab during 48-week treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-4/MIRANTIBUS
Journal: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
Published: August 10, 2023
Efficacy and safety of divozilimab during 24-week treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-2
Journal: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
Published: April 21, 2023
Last Updated: 09/26/2026